Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer

Urologia Internationalis

Volumn 76, Issue 1, 2006, Pages 27-30

  Froehner, Michael ^a   Hakenberg, Oliver W ^a   Koch, Rainer ^a   Schmidt, Uta ^a   Meye, Axel ^a   Wirth, Manfred P ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Benign prostate hyperplasia; Prostate cancer; Prostate specific antigen; ROC analysis

Indexed keywords

COMPLEXED PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TOTAL PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD LEVEL; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; MALE; MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; STATISTICAL ANALYSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 30644468230     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089731     Document Type: Article

References (17)

1. Hernandez J, Thompson IM: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004;101:894-904.
2. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP, Cheli CD: Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:1787-1791.
3. Herrmann W, Stöckle M, Sand-Hill M, Hübner U, Herrmann M, Obeid R, Wullich B, Loch T, Geisel J: The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen. Clin Chem Lab Med 2004;42:1051-1057.
4. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A, Marberger M: Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002;60(suppl 1):4-9.
5. Sözen S, Eskicorapci S, Küpeli B, Irkilata L, Altinel M, Özer G, Uygur C, Alkibay T, Özen H: Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a Prospective Multicenter Study. Eur Urol 2005;47:302-307.
6. DeLong R, DeLong D, Clarke-Pearson D: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
7. Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R: Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/ml range of total PSA. BJU Int 2004;94:47-50.
8. Martin B, Cheli CD, Lifsey D, Ward M, Pollard S, Jefferson L, Thiel RP, Rayford W: Complexed PSA performance for prostate cancer detection in an African-American population. Urology 2003;62:835-839.
9. Saika T, Tsushima T, Nasu Y, Kusaka N, Miyaji Y, Takamodo H, Takeda K, Uno S, Kumon H, for the Okayama Urological Cancer Collaborative Group: Prostate specific antigen complexed to α1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002;94:1685-1691.
10. 1-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10-30 μg/l. Clin Chem 2002;48:1251-1256.
11. Filella X, Truan D, Alcover J, Quinto L, Molina R, Luque P, Coca F, Ballesta AM: Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms. Urology 2004;63:1100-1103.
12. McArdle PA, Pollock MA, Wallace AM, McMillan DC, Crooks JE, Underwood MA: Comparison of total, complexed and free prostate-specific antigens and their ratios in the detection of prostate cancer in a non-screened population. Ann Clin Biochem 2004;41:201-206.
13. Ozdal OL, Aprikian AG, Begin LR, Behlouli H, Tanguay S: Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer. BJU Int 2004;93:970-974.
14. Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ: Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiol Biomarkers Prev 2004;13:1640-1645.
15. Okihara K, Ukimura O, Nakamura T, Mizutani Y, Kawauchi A, Naya Y, Uchida M, Ogiwara T, Miki T: Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men? Eur Urol 2004;46:57-64.
16. Djavan B: Editorial comment. Urology 2004;63:1103-1104.
17. Webber R: Editorial comment. BJU Int 2004;93:974.